Company intelligence / Profile preview
insitro
South San Francisco, California, USAinsitro.com ↗
- Ownership
- Private
- Employees
- ~150
- Development stage
- Other
01
Overview
insitro leverages a proprietary machine learning-based platform that integrates large-scale biological datasets with advanced computational models to accelerate drug discovery. The company focuses on metabolic diseases such as MASLD and obesity as well as neurodegenerative conditions like ALS. Most programs are in preclinical or research stages; no late-stage clinical results have been publicly reported yet.
- Therapeutic areas
- Metabolic DisordersEndocrinologyNeurology
- Modalities
- Small molecules (inferred from drug discovery focus)Potentially biologics (due to use of iPSCs and genome editing)Data-driven/AI-enabled therapeutics
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Not explicitly listed; open to strategic collaborations with pharma partners.
Beyond the preview
Go deeper on insitro.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on insitro.